Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Amortizatization of Intangibles of $388000.0 for Q1 2026, down 52.57% year-over-year from $818000.0 in Q1 2025, and up 26.8% quarter-over-quarter from $306000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $388000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 52.57% year-over-year to $388000.0; the TTM figure through Mar 2026 stood at $1.5 million (down 69.33% YoY), while the FY2025 annual figure was $1.9 million, down 58.25% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $388000.0, up from $306000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.8 million in Q3 2024, with the low at -$38000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $554000.0 (2024), against an average of $639588.2.
- Peak annual rise in Amortizatization of Intangibles reached 6540.0% in 2022, while the deepest fall reached 392.31% in 2022.
- Foghorn Therapeutics' Amortizatization of Intangibles stood at $574000.0 in 2022, then decreased by 13.76% to $495000.0 in 2023, then jumped by 216.97% to $1.6 million in 2024, then plunged by 80.5% to $306000.0 in 2025, then grew by 26.8% to $388000.0 in 2026.
- Business Quant data shows FHTX's Amortizatization of Intangibles at $388000.0 in Q1 2026, $306000.0 in Q4 2025, and $356000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | 618,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 618,000.00 |
| Mar 31, 2026 | 388,000.00 |
| Dec 31, 2025 | 306,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 705,000.00 |
| Mar 31, 2024 | 554,000.00 |
| Dec 31, 2023 | 495,000.00 |
| Sep 30, 2023 | 655,000.00 |
| Jun 30, 2023 | 731,000.00 |
| Mar 31, 2023 | 770,000.00 |
| Dec 31, 2022 | 574,000.00 |
| Sep 30, 2022 | 427,000.00 |
| Jun 30, 2022 | 332,000.00 |
| Mar 31, 2022 | -38,000.00 |
| Dec 31, 2021 | -97,000.00 |
| Sep 30, 2021 | -100,000.00 |